IPA Announces Onboarding of Clients Using IPA’s Proprietary High-Throughput B-Cell Select™ and DeepDisplay™

IPA is fully prepared to respond to the demand and use of alternative transgenic species in novel antibody generation.

ImmunoPrecise Antibodies' Subsidiary U-Protein Express Announces Exclusive Agreement as Global Supplier for Wnt- Surrogate-Fc Growth Factor

The Wnt-Surrogate-Fc Fusion Protein is an important growth factor in the field of organoid technology

ImmunoPrecise to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

Attendees will obtain corporate updates from the premier Canadian publicly traded and private companies through presentations and private meetings.

ImmunoPrecise Appoints Andy Nixon to Board of Directors

Dr. Nixon brings unique experience and expertise that is directly relevant to IPA.

TetraGenetics and ImmunoPrecise Extend Collaboration for the Discovery of Therapeutic Antibodies

The alliance is focused on the discovery of antibodies against three undisclosed therapeutically-relevant ion-channels.

ImmunoPrecise Antibodies Leverages Proprietary Technology and Expertise to Create Talem Therapeutics

Talem is focused on the discovery and development of fully human therapeutic antibodies.

Items 1 to 6 of 67 total

Show per page